Icad Current Deferred Revenue Over Time
| ICAD Stock | USD 1.77 0.04 2.31% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Icad Performance and Icad Correlation. Icad |
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.20) | Revenue Per Share 0.718 | Quarterly Revenue Growth 0.206 | Return On Assets (0.08) | Return On Equity (0.15) |
The market value of icad inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare icad inc and related stocks such as Profound Medical Corp, Si Bone, and Sight Sciences Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PROF | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 192.9 K | 192.9 K | 191.9 K | 229.5 K | 501.2 K | 358 K | 477 K | 471 K | 717.3 K | 383.6 K |
| SIBN | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 11.3 M | 11.3 M | 11.3 M | 11.1 M | 11.1 M | 11.1 M | 12.7 M | 9.6 M |
| NVRO | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | 43.3 M | (4.6 M) | (5.2 M) | 1.5 M | 1.4 M |
| FNA | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 10.6 M | 18.8 M | 148 K | 243 K | 230.8 K |
| SSKN | 106.3 K | 171.7 K | 171.7 K | 244 K | 43 K | 173 K | 235 K | 291 K | 2.1 M | 2.1 M | 2.3 M | 3.3 M | 2.8 M | 2.1 M | 2 M |
| AXGN | 1 M | (1.6 M) | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 33.3 K | 31.7 K | 18 K | 14 K | 14 K | 14 K | 14 K | 12.6 K | 12 K |
| AIMD | 739.7 K | 3.2 M | 1 M | (3.5 M) | 124.8 K | 124.8 K | 124.8 K | (145.6 K) | (145.6 K) | (145.6 K) | (145.6 K) | 112.6 K | 112.6 K | 101.3 K | 96.2 K |
| LNSR | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 923 K | 904 K | 768 K | 1.3 M | 1 M |
| NVNO | 138.7 K | 138.7 K | 138.7 K | 138.7 K | 138.7 K | 138.7 K | 340.5 K | 103.4 K | 33 K | 33 K | 33 K | 668.8 K | (427 K) | (384.3 K) | (365.1 K) |
| ESTA | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 2.3 M | 908 K | 785 K | 1.2 M | 769 K | 1.7 M | 1.8 M | 1.5 M |
| CVRX | (231 K) | (231 K) | (231 K) | (231 K) | (231 K) | (231 K) | (231 K) | (231 K) | (231 K) | (231 K) | (231 K) | (231 K) | (231 K) | (207.9 K) | (218.3 K) |
| SRDX | 303 K | 47 K | 43 K | 52 K | 48 K | 180 K | 62 K | 9.6 M | 5.6 M | 5.2 M | 4.6 M | 4.2 M | 4.4 M | 1.6 M | 2.4 M |
| BMRA | 263.3 K | 59.9 K | 50.7 K | 50.7 K | 50.7 K | 50.7 K | 50.7 K | 50.7 K | 50.7 K | 50.7 K | 50.7 K | 50.7 K | 60 K | 85 K | 80.8 K |
| MOVE | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.1 M | 1 M |
icad inc and related stocks such as Profound Medical Corp, Si Bone, and Sight Sciences Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| icad inc | ICAD |
Specialization | Health Care, Health Care Equipment & Services |
| Location | New Hampshire; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.77
Check out Icad Performance and Icad Correlation. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Icad technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.